Stroke--tPA and the Clinic
- 19 September 2003
- journal article
- policy forum
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 301 (5640), 1677
- https://doi.org/10.1126/science.1090270
Abstract
Clinical trial results are not always rapidly incorporated into routine medical practice. This Policy Forum describes a variety of barriers that have impeded the more widespread use of thrombolytic therapy (tPA, tissue plasminogen activator) for selected patients with acute ischemic stroke. These barriers are not insurmountable but will require a concerted effort to overcome.Keywords
This publication has 16 references indexed in Scilit:
- Guidelines for the Early Management of Patients With Ischemic StrokeStroke, 2003
- Telemedicine for Acute StrokeStroke, 2003
- Quality Improvement and Tissue-Type Plasminogen Activator for Acute Ischemic StrokeStroke, 2003
- Protocol Violations in Community-Based rTPA Stroke Treatment Are Associated With Symptomatic Intracerebral HemorrhageStroke, 2001
- Early stroke treatment associated with better outcomeNeurology, 2000
- Identifying Stroke in the FieldStroke, 2000
- North Carolina Stroke Prevention and Treatment Facilities SurveyStroke, 2000
- Cost-effectiveness of tissue plasminogen activator for acute ischemic strokeNeurology, 1998
- Do Practice Guidelines Guide Practice?New England Journal of Medicine, 1989
- Tissue Plasminogen Activator Reduces Neurological Damage After Cerebral EmbolismScience, 1985